[Imatinib in the treatment of chronic myelogenous leukemia]
Department of Science and Technology - Brazilian Health Technology Assessment General Coordination
Record ID 32006001463
Portuguese
Authors' objectives:
To evaluate the effectivenes and safety of imatinib for chronic myeloid leukemia.
Authors' recommendations:
Imatinib seemed to be superior to interpheronalpha plus cytabarine regarding cytogenetic and hematologic improvements. However, the evidence for reduction of mortality is insufficient, since longterm results are not yet available.
Details
Project Status:
Completed
URL for project:
http://portal.saude.gov.br/portal/arquivos/pdf/imatinib_for_chronic_myeloid_leukemia.pdf
Year Published:
2005
URL for published report:
http://portal2.saude.gov.br/rebrats/visao/estudo/detEstudo.cfm?codigo=304&evento=6&v=true
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Brazil
MeSH Terms
- Antineoplastic Agents
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Piperazines
- Pyrimidines
Contact
Organisation Name:
Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
Contact Address:
Ministerio da Saude, Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia, Esplanada dos Ministerios, Edificio sede; bl "G" - 8 andar - SL 834, CEP: 70058-900, Brasilia, DF Brazil, Tel: +55 61 3315 3197 Fax: +55 61 3315 3850
Contact Name:
suzanne.jacob@saude.gov.br
Contact Email:
suzanne.jacob@saude.gov.br
Copyright:
Department of Science and Technology - Brazilian Health Technology Assessment General Coordination (DECIT-CGATS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.